August 25, 2021
MedXCell Science SA:
MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the first time a French university hospital became a shareholder of a private company. As per the CHU, the University of Montpellier has recently acquired a stake in the company in order to strengthen the Group’s public-private collaboration with its academic partners. MedXCell Science leads several preclinical and clinical R&D programs around mesenchymal stromal cells (MSCs) and their application for the treatment of mild to moderate knee osteoarthritis, in close collaboration with academic clinical research at the IRMB in Montpellier.
MedXCell NKar SAS:
Founded in March 2020, MedXCell NKar is a biotechnology company active in the field of immunotherapy. It specializes in the development of therapeutic solutions combining Natural Killer (NK) cells and monoclonal antibodies. MedXCell NKar is a subsidiary of the Swiss group MedXCell. MedXCell NKar's ambition is to become a leader in the development of cell therapy products in immunotherapy thanks to its eNKab® platform.